StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Beam Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $408.66M, up 3.1% year over year. For fiscal 2025 it was $409.62M, up 11.4% from the year before. The highest annual figure on record is $437.38M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$409.62M+11.4%
FY2024Dec 31, 2024$367.56M-16.0%
FY2023Dec 31, 2023$437.38M+40.4%
FY2022Dec 31, 2022$311.59M-19.5%
FY2021Dec 31, 2021$387.09M+275.2%
FY2020Dec 31, 2020$103.18M+88.9%
FY2019Dec 31, 2019$54.62M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$95.10M-6.5%
Q1 FY2026Mar 31, 2026$104.52M+5.8%
Q4 FY2025Dec 31, 2025$99.28M-2.1%
Q3 FY2025Sep 30, 2025$109.77M+16.5%
Q2 FY2025Jun 30, 2025$101.76M+16.9%
Q1 FY2025Mar 31, 2025$98.82M+16.5%
Q4 FY2024Dec 31, 2024$101.44M-27.6%
Q3 FY2024Sep 30, 2024$94.26M-5.8%
Q2 FY2024Jun 30, 2024$87.04M-10.8%
Q1 FY2024Mar 31, 2024$84.82M-14.9%
Q4 FY2023Dec 31, 2023$140.08M+62.2%
Q3 FY2023Sep 30, 2023$100.05M+17.3%
Q2 FY2023Jun 30, 2023$97.61M+30.9%
Q1 FY2023Mar 31, 2023$99.65M+52.3%
Q4 FY2022Dec 31, 2022$86.34M-10.8%
Q3 FY2022Sep 30, 2022$85.29M+56.1%
Q2 FY2022Jun 30, 2022$74.56M+63.6%
Q1 FY2022Mar 31, 2022$65.41M-65.6%
Q4 FY2021Dec 31, 2021$96.78M+198.2%
Q3 FY2021Sep 30, 2021$54.62M+83.1%
Q2 FY2021Jun 30, 2021$45.58M+135.5%
Q1 FY2021Mar 31, 2021$190.11M+782.2%
Q4 FY2020Dec 31, 2020$32.45M+60.5%
Q3 FY2020Sep 30, 2020$29.83M+137.8%
Q2 FY2020Jun 30, 2020$19.35M+52.6%
Q1 FY2020Mar 31, 2020$21.55M+134.8%
Q4 FY2019Dec 31, 2019$20.22M–
Q3 FY2019Sep 30, 2019$12.54M–
Q2 FY2019Jun 30, 2019$12.68M–
Q1 FY2019Mar 31, 2019$9.18M–

More Beam Therapeutics figures

See a number that looks wrong?